News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Research & Diagnostic Antibodies Receives Allowance for Key SIRS/Sepsis Diagnostic Patent in Europe



10/28/2009 10:02:49 AM

LAS VEGAS--(BUSINESS WIRE)--Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology. This notification is equivalent to a “Notice of Allowance” by the United States Patent Office. European patent application 01959345 covers very broadly the use of R&D Antibodies’ immunoassays, kits, and apparatuses for the detection of plasma iNOS as a biomarker for the prognosis and diagnosis of Systemic Inflammatory Response Syndrome (SIRS) that will deteriorate into sepsis. This European Patent Office allowance of claims extends R&D Antibodies’ existing patent portfolio in this field (USA #6531578-B1 and 7198904-B1, European #EP1012605, Japan #4117911, and Australian #2001280912 and 782922). Equivalent patent applications are also pending in the USA, Japan, Australia and Canada.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES